Remaining Challenges in Childhood Cancer and Newer Targeted Therapeutics
- 1 February 2015
- journal article
- review article
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 62 (1) , 301-312
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancerPediatric Blood & Cancer, 2014
- Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric ApplicationsFrontiers in Oncology, 2014
- Potent inhibition of DOT1L as treatment of MLL-fusion leukemiaBlood, 2013
- Chromatin Remodeling Defects in Pediatric and Young Adult Glioblastoma: A Tale of a Variant Histone 3 TailBrain Pathology, 2013
- Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical ResponseClinical Cancer Research, 2012
- Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcomeBlood, 2010
- Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009
- Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome InhibitionCancer Research, 2007
- Antitumor activity of sorafenib in FLT3-driven leukemic cellsLeukemia, 2007
- Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening TrialsJournal of Clinical Oncology, 2005